AYTU BIOPHARMA, INC Long-Term Debt, Maturity, Remainder of Fiscal Year
AYTU BIOPHARMA, INC (AYTU) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $464.00 thousand as of 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2026-05-13
- 2026-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $464.00K.
- 2025-12-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $928.00K.
- 2025-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $1.39M.
- 2025-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $464.00K.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2026-03-31 | $464.00K 10-Q · filed 2026-05-13 |
| 2025-12-31 | $928.00K 10-Q · filed 2026-02-03 |
| 2025-09-30 | $1.39M 10-Q · filed 2025-11-13 |
| 2025-03-31 | $464.00K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $928.00K 10-Q · filed 2025-02-12 |
| 2024-09-30 | $1.39M 10-Q · filed 2024-11-13 |
| 2024-03-31 | $16.00K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $39.00K 10-Q · filed 2024-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |